KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Retained Earnings (2016 - 2025)

Travere Therapeutics' Retained Earnings history spans 15 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 1386.25% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$1.2 million, down 1386.25%, while the annual FY2025 figure was -$1.2 million, 1386.25% down from the prior year.
  • Retained Earnings reached -$1.2 million in Q4 2025 per TVTX's latest filing, down from -$1.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $303000.0 in Q3 2022 to a low of -$1.5 billion in Q1 2025.
  • Average Retained Earnings over 5 years is -$606.8 million, with a median of -$722.4 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: skyrocketed 157.71% in 2022, then plummeted 341832.34% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$766.0 million in 2021, then tumbled by 32.41% to -$1.0 billion in 2022, then skyrocketed by 99.86% to -$1.5 million in 2023, then soared by 94.51% to -$80000.0 in 2024, then plummeted by 1386.25% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Retained Earnings are -$1.2 million (Q4 2025), -$1.1 million (Q3 2025), and -$812000.0 (Q2 2025).